
    
      Patients will receive a single oral dose of CRA-024781 one week before beginning intravenous
      dosing. Blood samples for pharmacokinetic and pharmacodynamic analysis will be collected on
      several occasions prior to the start of the intravenous treatment.

      The intravenous treatment will consist of 3 consecutive days of CRA-024781 IV administered as
      a 2-hour IV infusion every 3 weeks in a 4 weeks cycle.

      Assessment of the extent of disease will be performed every 8 weeks.
    
  